Enveric Biosciences' EB-003 Significantly Reduces PTSD Fear Response
Enveric Biosciences highlighted preclinical data for its lead candidate, EB-003, a dual 5-HT2A and 5-HT1B modulator, in which a single dose of EB-003 significantly reduced context-induced freezing behavior one hour post-dose. These results indicate a rapid reduction in conditioned fear response in a validated preclinical model of post-traumatic stress disorder. President Donald Trump's April 18, 2026, Executive Order supporting research into psychedelic therapies for mental health conditions, including PTSD, highlights increasing recognition at the federal level of the urgent need for novel treatment approaches. President Trump stated, "In many cases, these experimental treatments have shown life-changing potential for those suffering from severe mental illness and depression." Secretary of Health and Human Services Robert F. Kennedy Jr commented, "At the same time, millions of Americans living with depression, PTSD, addiction and other conditions do not respond to existing treatments."
